Introduction: Colorectal cancer (CRC) is a disease predominantly affecting older individuals. Recent studies suggested a constantly rising incidence in young age worldwide. We noticed increased incidence of early onset CRC at our institution. The aim of this study is to assess the incidence, the clinicopathological features and survival of CRC patients in young age in comparison to standard age. Methods: This is a retrospective study that included all CRC patients who were diagnosed and treated in the National Cancer Institute, Cairo University between 2008 and 2012. Data on the patient characteristics and clinical outcomes were collected and evaluated. Results: Through this period, 607 patients were assessed. the median follow up period was 26 months (range; 2-163 months). The mean age 6SD of the included patients was 49.1 614.3 years while the median was 50 years (ranging from 16 to 85 years) with slight female predominance. Thirty percent of patients were 40 years. Compared to standard age group, younger age patients ( 40 years) had significantly less co-morbidities, better ECOG performance status and higher incidence of left-sided cancer location (p ¼ 0.001, p ¼ 0.002 & p ¼ 0.03 respectively). They also presented with significantly higher pathological grade, higher incidence of mucinous histological type, and more node-positive disease (P < 0.001 for all). Standard age had significantly high preoperative CEA and higher incidence of metastatic disease (p ¼ 0.046 & p ¼ 0.001 respectively) while younger age had significantly higher incidence of stage III disease and significantly more exposed to chemotherapy (p ¼ 0.001 for both). However no significant differences were found between both groups regarding event free or overall survival. Conclusion: There is an alarming higher incidence of younger age at presentation of CRC in Egypt with unfavorable biological behavior. However there was no significant impact of age on survival. Further larger trials are warranted to explore the possible environmental and molecular background behind this trend. In 86% cases A combination therapy was used as a second line. Only 44% of pts received full dose FOLFIRI-A. Median administered cycles number was 6 (Range 1-61) ORR was 24% (PR) and 33% achieved SD. Median PFS was 6.4 months (95%CI 5.3 -7.4). 49% of pts received at least 1 more line after A progression. Median OS (from beginning of A therapy) was 11.9 months (95%CI 9 -14.8) Main grade 3 3 observed toxicities were neutropenia (16.2%), fatigue (6%) and diarrhea (5.4%) Class toxicity: 40% pts developed any hypertension grade (7.2% grade ! 3) and 6% had a grade ! 3 thromboembolic event during A therapy. There was no interaction between PFS with A treatment and age (< vs > 70y), presence of RAS/BRAF mutation or MSI-H, number of metastatic sites, metastatic debut, first line therapy, and dose reduction FOLFIRI or not. ORR was significantly higher with full dose FOLFIRI-A vs suboptimal chemotherapy combinations (30 vs 19% PR p < 0,05). Pts with left tumors (6.6 vs 4.9 m), surgery of primary tumor (6.6 vs 5.2 m) and ECOG 0/1 (6.4 vs 3 m) showed significantly higher PFS. In terms of OS, left tumors (13.5 vs 8.1 m) and pts with surgery of primary tumor (16.3 vs 8.1 m) achieved better clinical outcomes. Metachronous debut (42.5 vs 10.2 m), 1 metastatic site (14.5 vs 9 m), PR with first line (12.8 vs 8.4 m) and systemic treatment after A progression (16.3 vs 7.7 m), were also found as favourable prognostic factors for OS. Multivariate analysis showed significant association between ECOG and PFS, first line radiological response, post-aflibercept therapy and OS. Primary tumor location and number of metastatic sites were also associated with both, PFS and OS. Conclusion: We reproduce VELOUR trial efficacy and safety results in our heavily treated population. ECOG and treatment lines are relevant issues in terms of PFS and OS respectively. Primary tumor location seems a strong prognostic factor for PFS and OS.
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